Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

7.9K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.9K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

12.2K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
12.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

792
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
792
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.3K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of CD34-positive cells enumeration using ADAMII image-based fluorescence cell counter with fluorescence flow cytometry.

Clinical chemistry and laboratory medicine·2026
Same author

Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

Therapeutic advances in neurological disorders·2026
Same author

Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.

Blood advances·2026
Same author

A freeze-dried platelet-derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus-formation analysis system 01.

Transfusion·2026
Same author

Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.

British journal of haematology·2026
Same author

Blood collection establishments' partnerships with human milk banks: An operational diversification and community service avenue.

Vox sanguinis·2026

Related Experiment Video

Updated: Nov 3, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.1K

Pathogen inactivation of platelets for transfusion.

Joan Cid1, Miquel Lozano1

  • 1Apheresis & Cellular Therapy Unit, Department of Hemotherapy & Hemostasis, ICMHO, IDIBAPS, UB,Hospital Clínic,Barcelona, Catalonia, Spain.

Platelets
|June 7, 2021
PubMed
Summary

Pathogen inactivation methods enhance platelet transfusion safety by reducing bacterial contamination risks. While slightly reducing platelet efficacy, these methods are deemed beneficial for preventing transfusion-transmitted infections.

Keywords:
Pathogen inactivation methodsplatelet transfusionsafety

More Related Videos

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

13.8K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.2K

Related Experiment Videos

Last Updated: Nov 3, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.1K
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

13.8K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.2K

Area of Science:

  • Transfusion Medicine
  • Blood Component Safety
  • Pathogen Reduction Technologies

Background:

  • Bacterial contamination is a significant risk in blood component transfusion, especially for platelets stored at room temperature.
  • Platelet components have a short shelf-life of 5 days due to storage conditions.
  • Pathogen inactivation (PI) methods offer a proactive strategy to mitigate infectious agent transmission.

Purpose of the Study:

  • To evaluate the benefits and risks of pathogen inactivation methods in platelet transfusion.
  • To assess the clinical efficacy of pathogen-reduced platelets compared to standard platelet components.

Main Methods:

  • Review of available pathogen inactivation technologies, primarily using UV light with or without photosensitizers.
  • Analysis of clinical trial data comparing pathogen-reduced platelets with non-inactivated platelets regarding efficacy and safety outcomes.
  • Evaluation of key performance indicators such as platelet count, corrected count increment, and transfusion intervals.

Main Results:

  • Pathogen inactivation offers benefits including inactivation of known and unknown pathogens, residual leukocyte reduction, and extended storage from 5 to 7 days.
  • Pathogen-reduced platelets show a lower platelet yield, reduced 24-hour corrected count increment, and shorter transfusion intervals post-inactivation.
  • Eight of nine randomized controlled trials indicated non-inferiority of pathogen-reduced platelets compared to standard components in preventing bleeding episodes.

Conclusions:

  • Pathogen inactivation methods significantly enhance the safety of platelet transfusions by reducing the risk of bacterial contamination.
  • Despite a trade-off in platelet efficacy (e.g., reduced platelet count and increment), the overall benefit of increased transfusion safety is considered worthwhile.
  • The use of pathogen inactivation technologies is a valuable strategy in transfusion medicine for improving patient outcomes.